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Abstract
This chapter focuses on the eye, one of the most important organs of humans. Current
data on pathophysiology of the human eye are presented in direct correlation with a range
of therapeutic products, with a well-known and widely used material, namely chitosan.
Applications of chitosan biopolymer are described in the development of innovative,
modern, therapeutic devices and solutions. Thus, chitosan is a good excipient either for
classic drop-type ocular systems, as well as for complex drug systems such as nanostr-
uctures (nanoparticles, nanomicelles and nanosuspensions), liposomes, microemulsions,
microspheres, in situ hydrogels and inserts or implants. A number of disadvantages for
ocular administration of the drugs are thus overcome.
Keywords: chitosan, ocular, delivery systems
1. Introduction
As fascinating as its perfect structure, so difficult to approach due to increased sensitivity and
many protective barriers, the human eye continues to be a brainstorming of ideas to formulate
and characterize pharmaceutical preparations with optimal action at this level.
The eye can be structured into two large segments: anterior and posterior, the latter representing
about two-thirds of the total area. The anterior segment includes the cornea, the conjunctiva, the
iris, the lens, the ciliary body and the aqueous humor. Sclera, choroid, retina, vitreous humor and
optic nerve are parts of the posterior segment [1].
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Following eye drops, the bioavailability of the drug is less than 5% [2] due to factors such as
nasolacrimal drainage, lacrimation induction, blink reflexion or corneal barrier [3]. Pharma-
ceutical formulations given intraocular must be sterile, without pyrogens or endotoxins, iso-
tonic, isohydric and stable. The eye tolerates a pH between 7.5 and 9.5. Alkaline solutions are
better supported [4].
Due to the occurrence of diseases such as glaucoma [5], age-related macular degeneration [6],
diabetic macular edema [7], diabetic retinopathy [8] or dry eye syndrome [9], which require
drug delivery for a prolonged period, it has become necessary to create pharmaceutical for-
mulations that provide sustained release, increased bioavailability with decreased frequency
of administration. A significant challenge in achieving this goal is to overcome ocular barriers
without causing permanent tissue damage [10].
Introduced on market in 1990, chitosan was the source of numerous studies to harness its
potential as pharmaceutical excipient [11]. Obtained by deacetylation of chitin, the second
most abundant polysaccharide after cellulose, chitosan consists of D-glucosamine and N-acetyl
D-glucosamine linked β-(1-4) [12]. Mucoadhesiveness, biodegradable, biocompatible and non-
toxic nature make it a suitable candidate for ocular formulations. Chitosan solutions have
pseudoplastic and viscoelectric properties that do not disturb the pre-corneal tear film [13].
New formulations and devices have been obtained to ensure an increased retention time and
thus a superior drug delivery system using nanomicelles, nanosuspensions, liposomes, in situ
gels, inserts and contact lens [14].
2. Chitosan-based drug delivery systems for ocular administration
2.1. Physiopathology of the eye
The eyeball has a spherical shape and an antero-posterior diameter of about 24 mm. It is
structured in to two segments: anterior and posterior (Figure 1). The anterior segment of the
eye comprises the cornea, conjunctiva, iris and ciliary body, crystalline and aqueous humor
[15]. Cornea is transparent, avascular, composed of five layers and provides optimal light
transmittance [16]. It continues with sclera through the limbus [17] and the conjunctiva. The
conjunctiva is a thin, strongly vascularized, porous [18] membrane where mucus-producing
goblet cells are located. The mucin layer interacts with the corneal glycocalyx, facilitating the
spreading of the tear film [19]. Aqueous humor provides nutrients needed for the cornea and
maintains intraocular pressure at the optimum value [20].
To maintain intraocular pressure at normal values between 12 and 20 mmHg, a proper opening
of the anterior chamber angle is required to allow an evacuation of excess through the trabecular
meshwork [21]. In the posterior segment of the eye are sclera, choroid, retina, vitreous humor
and optic nerve. Choroid has the role of reducing the amount of light that reaches the retina,
contributes to thermoregulation through the dissipation of heat and influences the intraocular
pressure through the vasculature [22].
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The retina is a thin and transparent tissue, made up of 10 layers in which there are two types of
receptors: cones and rods. These receptors convert photons into nerve impulse that reaches the
brain through the optic nerve [23].
Glaucoma [24–27], conjunctivitis, blepharitis [28], keratitis, dry eye syndrome [29, 30] affect
anterior eye segment [31], while posterior segment disorders affecting the vision and even
causing complete loss of it: diabetic retinopathy [32], macular degeneration, macular edema
and uveitis [33, 34].
Recent studies have made correlations between glaucoma and Alzheimer’s disease. Both
chronic conditions cause the accumulation of β amyloid associated with inflammatory pro-
cesses, the appearance of reactive oxygen species and cell apoptosis [35].
The eye is protected by two types of barriers: static and dynamic. Cornea, conjunctiva,
ciliary body, aqueous humor and retina are static barriers, while blood flow or lacrimal flow
are dynamic barriers. There are situations when their alteration can lead to ocular lesions or
hypotonia. The latter consists of penetrating serum proteins into the anterior and posterior
rooms with the appearance of edema [36]. Molecules up to 20 kDa can cross the conjunctiva
while those up to 5 kDa cornea [37]. In pathological situations, blood retinal barrier alter-
ation causes the permeation of proteins to the retina with the appearance of edema and
alteration of vision [38]. In diabetic retinopathy, elevated levels of vascular endothelial
growth factor and NO increase the level of reactive oxygen species that generate oxidative
stress with neovascularization [39]. The main protector against chemical or microbial
aggression is the tear film, a mixture of lacrimal fluid and mucin, an O-glycosylated glyco-
protein [40]. It is composed of three different layers [41]. The pH of the tear fluid is about
7.4. It decreases on awakening by the loss of CO2 resulting from anaerobic metabolism
during sleep and increases at contact lens wearers, dry eye syndrome or lacrimal stenosis
[42]. Aquaporins play an important role in the transmembranar movements of water
through the cornea and conjunctiva in the tear fluid while maintaining the osmolarity of
the film [43].
Figure 1. Anatomy of the eye.
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2.2. Chitosan
The benefits of polysaccharides consist of natural abundance, the presence of functional groups
available for chemical alterations, and the disadvantages include varied properties depending on
the origin, microbial contamination or low microbial resistance [44].
The discovery of chitosan is attributed to Rouget in 1859 when he noticed that he can bring
chitin in a soluble form by submitting it to various chemical and thermal treatments [45].
This natural polysaccharide (Figure 2) has increased interest because it is non-toxic, biocompat-
ible, biodegradable with various applications in tissue engineering [46–49], food as preservative
[50, 51], ruminants’ fermentation process [52], in water treatment, medicine and pharmacy as
wound dressing [53], implants and medicinal products [54–56]. It is often obtained by deacety-
lation with an aqueous solution of NaOH from chitin, a polysaccharide from crustaceans’ exo-
skeleton (lobster, crab, squid and shrimp), some fungi and insects [11], insoluble in water but
soluble in solutions of dilute acids such as acetic, citric, tartaric and hydrochloric acid at pH < 6.5.
It is not soluble in phosphoric or sulfuric acid [57]. This behavior is explained by the protonation
of amino groups with the formation of inter-molecular repulsions [11]. It can be dissolved in
neutral medium in presence of glycerol-2-phosphate [58].
Biological actions include antimicrobial, antioxidant [59], antiviral [60], antitumoral, antithro-
mbotic and antifungal activity [61]. The positive charge of the molecule binds to the fungal cell
membrane, produces an alteration of the K and Ca flux with inhibition of respiration and ferme-
ntation [62]. The anti-obesity effect is due to the ability to bind lipids, decreasing their absorption
in the digestive tract [63].
Mucoadhesive properties are due to the positive charge that allows interaction with sialic acid
from mucin, negatively charged, with the formation of electrostatic bonds [56].
The properties of chitosan are influenced by molecular weight and degree of deacetylation. The
biodegradation rate of the polymer is determined by the content in acetyl groups [64]. A degree of
deacetylation of 85% or more is preferred due to strong mucoadhesive properties and biocompat-
ibility [65]. In order to obtain oligosaccharides, enzymatic methods are preferred with the use of
Figure 2. Structure of chitosan.
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chitosanases, enzymes with high specificity [66]. Oligosaccharides have anti-inflammatory,
antitumoral [67] and antimicrobial action [68].
Low molecular weight chitosan derivatives exhibit water solubility in a wide range of pH, low
viscosity and superior biological activities: bactericidal, immunomodulatory, antitumoral,
hypolipidemic and hypocholesterolemic [69]. The reactive groups of chitosan are the amino
group of C2 and the hydroxyl groups of C3 and C6. Positions C2 and C6 are favorable for
substitution. Substitution with carboxymethyl or succinyl groups at this level increases the
solubility of the compounds. Due to the presence of a carboxyl group, they can bind calcium,
depriving the extracellular matrix of Ca. ions. Thus, they alter tight junctions and its perme-
ability and facilitate paracellular transport through the epithelium. [58]. Chitosan thiolated
compounds known as thiomers have strong mucoadhesive properties, increased permeability,
antiproteasic activity [70] and inhibit efflux pump [71]. Thiolated derivatives are conjugates
with thioglycolic acid or cysteine (Figure 3). They exhibit paracellular permeability through
the mucosa, forming gels at pH between 5 and 6.8. [72]. Chitosan-N-acetylcysteine has been
approved on the market as eye drops under the name Lacrimera, with increased mucoad-
hesive properties [73].
2.3. Advanced drug delivery technologies
Different strategies have been approached to increase the bioavailability of drug substances
at the eye level: increased corneal permeability (prodrugs, permeability enhancers and
cyclodextrins), increased viscosity of the vehicle (suspensions, ointments and gels in situ),
use of dispersion systems (liposomes, emulsions and nanoparticles), increasing contact time
with solid matrix (inserts and contact lenses) [74]. In order to increase eye retention time and
reduce the frequency of administration, it is preferred to use natural polymers such as chito-
san, gelatin, sodium alginates, sodium hyaluronate, etc. (Table 1). At the same time, they are
biocompatible, biodegradable and non-toxic [75]. Other advantages of these polysaccharides
include natural abundance, nature-friendly materials, relative ease of isolation and low cost
[44]. At the same time, they are biocompatible, biodegradable and non-toxic [75]. Other
advantages of these polysaccharides include natural abundance, nature-friendly materials,
relative ease of isolation and low cost [44].
Figure 3. Structures of thiolated chitosans: chitosan-cysteine (left) and chitosan thioglycolic acid.
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Chitosan increases contact time with cornea, the most commonly used are low molecular
weight derivatives [80]. Nanotechnology has been developed to overcome eye barriers and
protect active substances [81]. Mucoadhesive nanocarriers increase eye contact time and act as
permeability enhancers (Figure 4) [82–84].
Thus, innovative formulations have been developed for the anterior segment of the eye, such
as preparations based on semifluorinated alkanes applied easy as drops or spray [85], micelles,
in situ gels, liposomes, contact lenses [86], inserts [87], dendrimers [88, 89], mini-tablets [90],
microspheres [91], nanowafers [92], ocular ring [93] or punctal plug systems [94]. For the
posterior segment: micro, nanoparticles, hydrogels, implants and microneedles [95–98].
Characterization of ophthalmic pharmaceutical forms is performed by in vitro and in vivo tests.
Determinations include sterility, pH, particle size, viscosity, stability, active substance content
and in vitro release. Toxicity studies include the Draize test [99] and the Hen’s egg test chorioal-
lantoic membrane (HET-CAMTest) [100]. Particularly, the oxygen permeability is determined for
Polymer Charge Solubility Properties Ocular dosage
forms
References
Chitosan Positive Insoluble in water, soluble in
solutions of dilute acids such
as acetic, citric, tartaric,
hydrochloric acid at pH <6.5.
It is not soluble in
phosphoric or sulfuric acid
Mucoadhesive,
biodegradable,
biocompatible and non-toxic,
pseudoplastic and
viscoelastic properties
similar to tear film.
In situ gels,
nanoparticles,
liposomes,
micelles
microspheres,
inserts,
[13, 57, 76]
Sodium
hyaluronate
Negative Soluble in water at room
temperature and acidic pH
Biodegradable, viscoelastic
properties
In situ gels [75, 77]
Carrageenan Negative Soluble in water, insoluble in
organic solvents
Gelling, thickening and
stabilizing properties,
gelification in presence of
Ca2+
In situ gels,
microspheres
[58, 75, 78]
Sodium
alginate
Negative Soluble in water, acidic pH.
Divalent cations decrease
solubility
Gelification in presence of
Ca2+, low toxicity,
biocompatibility,
biodegradability
Ocular mini-
tablets,
microspheres
[58, 75, 77]
Dextran
sulfate
Negative Soluble in water Viscosifying, emulsifying,
texturizing, stabilizing
properties. Excellent
biocompatibility and clinical
safety
In situ gels [58, 75, 78]
Colagen Amphoteric Soluble in acidic pH Very compatible with ocular
tissues
Ocular films,
ocular inserts
[75, 78]
Gelatin Amphoteric Soluble in water Excellent biocompatibility,
ease of processing and
availability at low cost
Ocular films [75, 78, 79]
Xanthan
gum
Negative Soluble in water, insoluble in
organic solvents
Swelling in basic
environment
Viscosity
enhancing
solutions, gels
[58, 75]
Table 1. Natural polymers used in ocular drug delivery systems to increase eye retention time.
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the lenses, and for the inserts and the contact angle [101]. Measuring the degree of drug release
in vitro is vital in the development of a pharmaceutical product, the best known way being with
Franz’s diffusion cell [102, 103] In a Franz cell, consisting of two compartments separated by an
artificial membrane and filled with simulated biological fluid, the formulation to be analyzed is
placed. Holding at 37C, samples are taken at certain time intervals and analyzed to determine
the concentration of the substance that crossed the membrane [104].
2.3.1. Nanoparticles
In nanotechnology, the particle size should be between 30 and 200 nm, they should be stable,
biocompatible and biodegradable [105]. Chitosan nanoparticles are formed spontaneously by
mixing a solution of chitosan with tripolyphosphate (TPP) to form inter and intramolecular
bonds. The main mechanism underlying the incorporation of active substances is the occur-
rence of electrostatic interactions with positively charged chitosan or negative TPP [106].
Basaran et al. have prepared and evaluated chitosan nanoparticles to enhance the ocular
permeability of ornidazole for the treatment of bacterial ocular infections. These were prepared
by spray-drying method. The nanoparticles were analyzed by morphology, pH, concentration
in active substance, in vitro release profile. In 24 h, 98% of the amount of ornidazole was in the
simulated biological medium. The authors consider the formulation to be safe and effective for
the release of ornidazole at the posterior segment [107].
For the treatment of bacterial endophthalmitis, Silva et al. incorporated daptomycin into chitosan
nanoparticles. The preparation was carried out by the ionotropic gelling method, which was
subsequently evaluated together with antimicrobial efficiency and stability in the presence of
lysozyme and mucin. Using SEM, the particle size was evaluated at about 200 nm. The degree of
incorporation varies between 80 and 97%. Total daptomycin release was achieved in 4 h. Incu-
bation with lysozyme did not affect the integrity of nanoparticles [108].
The efficacy of the chitosan-alginate nanoparticles loaded with betamethasone Na phosphate
in the treatment of macular edema was studied. With particle size between 16.8 and 692 nm, a
rapid initial release was noted, followed by a slow release during 24–72 h [109].
Figure 4. Comparison between different nanostructures.
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Chitosan nanoparticles were formulated and evaluated by Selvaraj et al. as a potential acyclo-
vir release system at the eye for the treatment of viral diseases. Nanoparticles were prepared
by ionic gelling and characterized by SEM, DSC and FTIR. The particle size was between 200
and 495 nm, the encapsulation efficiency was between 56 and 80% and the loading capacity
was 10–25%. In vitro release studies demonstrated a sustained release for 24 h, the kinetic
release profile following the Higuchi model [110].
The study tracks the potential of montmorillonite in the preparation of prolonged ophthalmic
nanoparticles. The nanoparticles were prepared by ionic gelling of chitosan with sodium trip-
olyphosphate. With a spherical shape between 358 and 585 nm and an incorporation efficiency of
between 12.27 and 50.92%, nanoparticles release betaxolol within 10 h, being effective in the
treatment of glaucoma [111].
The sustained release of celecoxib from the nanoparticles of chitosan and alginate was proposed
by Ibrahim et al. Various blends of polymers were prepared in varying proportions in order to
obtain the optimal formulation with the smallest particle size and the highest potential zeta.
Nanoparticles were included in collyria, in situ gels and preformed gel. With TEM, spherical
particles with an incorporation efficiency of over 75% have been shown. The release of active
substance followed the Higuchi model, and the formulations proved to be non-toxic according
to in vivo studies [112].
2.3.2. Nanomicelles
Nanomicelles, amphiphilic molecules that have the ability to form in an aqueous medium
organized supramolecular structures, contribute to the solubilization of hydrophobic active
substances.
A positive-load nanomicelle increases the retention time and the permeability due to interac-
tions with the negatively charged eye surface. Changing its surface by the addition of a
cationic polymer such as chitosan increases contact time to the eye [113].
Another study has proposed the formulation of pluronic/chitosan nanoparticles whose surface
has been modified by adding chitosan in order to increase the ocular bioavailability of
metipranolol. Nanomicelles were analyzed by diameters, morphology, turbidity, stability and
in vitro release. The drug nanoparticle size ranged from 123 to 232 nm with a zeta potential
between 6.1 and 9.2 mV. According to the turbidity test, the micelles were stable, preventing
the vision from collapsing. The release was 88% in 6 h [114].
A study designed to evaluate rapamycin ocular release from octanoyl-g-chitosan-g-PEG
nanomaterials was initiated by Somavarapu et al. Micelle size was determined using dynamic
light scattering (DLS), surface morphology with transmission electron microscopy (TEM) and
thermal properties with differential scanning calorimetry (DSC). The concentration in the
active substance was determined by the HPLC method. Following the study, nanomicelles
with a size of 52 nm were obtained and positively charged. The formulation remained stable
for 3 days. On visual analysis the preparation is clear with a dispersion index of 0.25. Tissue
retention was 24 h [115].
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2.3.3. Nanosuspensions
Shi et al. have formulated a chitosan and methoxy polyethylene glycol-poly (β-caprolactone)
nanosuspension for the ophthalmic delivery of diclofenac. Nanosuspension was characterized
by FTIR, X-ray diffraction and DSC. Nanosuspension was stable at 4 and 25C for 20 days.
Prolonged release of diclofenac was achieved for 8 h without irritation [116].
A nanosuspension of chitosan, sodium alginate and tripolyphosphate was developed as an
efficient delivery system of lomefloxacin. Nanosuspension was evaluated for particle size, zeta
potential, incorporation efficiency and permeability through the bovine cornea. The incorpo-
ration efficiency of the active substance was 70.63%, particle size 176  0.28 nm, zeta potential
13.65 mV. Nanosuspension releases lomefloxacin for more than 8 h and a three-fold increase in
bovine corneal permeability to solutions is noted. Also, administration of lomefloxacin in the
form of nanosuspension provides the advantage of a prolonged action, protects against
enzyme metabolism and increases corneal permeability. Chitosan possesses antimicrobial
activity, potentiating the effect of the antibiotic [117].
A chitosan-based nanosuspension with the active substance itraconazole is prepared by co-
precipitation. It has been noticed that co-precipitation of itraconazole from the chitosan- lysine
system in the presence of poloxamer 100 as a stabilizer causes a nanosuspension with the
smallest size, increases drug solubility 12-fold and a very fast in vitro release. Comparative
assessment with a commercial suspension determines a significantly increased permeability on
the goat’s cornea in the first case [118].
2.3.4. Liposomes
Introduced as drug carriers in 1968 [114], liposomes are membrane vesicles composed of one
or more phospholipidic or cholesterol layers designed to transport drug substances incorpo-
rated either into the core or into one of the layers [36]. They are biodegradable and biocompat-
ible, increasing the permeability of the drug with increasing retention time. These can be
administered at both the anterior and posterior segment.
Chitosan-coated liposomes, called chitosomes, increase ocular retention with decreased metab-
olism of drug substances. Coating liposomes with quaternary ammonium chitosan derivatives
such as N-trimethylchitosan reduces particle aggregation due to steric stability and increases
mucoadhesiveness [119].
Liposomes with an incorporation efficiency of more than 90% bromfenac were prepared for
targeting the retina. Changing liposome surface with chitosan improves mucoadhesive prop-
erties. The optimal concentration of chitosan that prevents liposome aggregation was deter-
mined at 0.15% [120].
A potential carrier for ocular drug release were low molecular weight chitosan-based lipo-
somes formulated by Li et al. Liposomal morphology was examined with TEM, and cytotox-
icity was assessed in rabbit conjunctival cells. By incorporating cyclosporin A, a delayed
release profile was revealed as compared to un-coated liposomes. In vivo studies showed that
the concentration of cyclosporin in different ocular tissues increased over 24 h [121].
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The objective of the study initiated by Ustundag-Okur et al. has been exploiting the potential of
nanostructured lipid carriers with chitosan for ocular application of ofloxacin. Particle character-
ization involved determining the size, potential zeta, viscosity, incorporation efficiency, active
substance load or sterility. According to the authors, the system has a 48-h corneal retention time
and a substance incorporation efficiency of over 97%. Chitosan improves transcorneal perme-
ability [122].
2.3.5. Microemulsions
The use of microemulsions as drug delivery systems offers advantages such as thermodynamic
stability, increased eye retention, improved absorption, incorporation of substances in any of
the two phases [123].
Bhosale et al. have formulated several chitosan-based microemulsions as a potential
voriconazole release system at the eye level. The formulations were evaluated for thermody-
namic stability, physico-chemical parameters, in vitro and in vivo release studies. All the
formulations have a particle size of less than 250 nm, potentially zeta positive. In vitro delivery
tests have shown that the formulations have a sustained release of over 12 h compared to
market formulations. Following in vivo studies in rabbits, it was concluded that the formula-
tions showed an active substance concentration of more than 47% in aqueous humor at 4 h
after administration compared to the product Vozole with a voriconazole concentration of
approximately 20% [124].
The evaluation of the tear retention of a chitosan-based emulsion containing indomethacin was
carried out by Yamaguchi et al. This was compared to a non-chitosan emulsion after instilla-
tion in rabbits. The chitosan emulsion has an average concentration of 3.6 and 3.8 higher than
that without chitosan at 0.5 and 0.75 h after instillation. The average residence time and half-
life for the chitosan emulsion were 1.5 times and 1.8 times higher than the comparative
emulsion. It has been appreciated that the chitosan emulsion has a prolonged lacrimal reten-
tion time and a wide distribution on the ocular surface due to the mucoadhesive properties of
chitosan [125].
2.3.6. Microspheres
Chitosan microspheres determine a controlled release of drug substances and increase the
bioavailability of drugs, improving the absorption of hydrophilic substances at epithelial level.
They facilitate the transport of substances to the eye or accumulation at the corneal or conjunc-
tival level [126].
Chitosan-based microspheres loaded with ganciclovir were prepared by Kapanigowda et al.
Characterization of the formulation was achieved by in vitro release studies, release kinetics
and stability of microspheres. The degree of eye irritation, pharmacokinetic parameters and
histopathology were evaluated on Wistar rats. In vitro release studies showed an initial burst
in the first few minutes, the diffusion following Fick’s law. Stability studies were favorable and
it was determined that in 75 h, three administrations of this formulation were needed com-
pared to six administrations of ganciclovir as a solution [127].
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A study initiated by Rajawat et al. has proposed to develop chitosan and chitosan-N-acetyl
cysteine-based microspheres as possible ocular delivery system for acyclovir. The formulations
were prepared using emulsification crosslinking process, the microspheres having an active
substance incorporation efficiency of 97.86  2.06% for the chitosan microspheres and
76.99  1.14% for the thiolate derivatives. In vitro release studies showed an initial burst
followed by a sustained release of acyclovir for 12 h, and in vivo studies did not indicate signs
of ocular toxicity [128].
2.3.7. Hydrogels in situ
In situ gels have shown interest since the 1970s.The first gel was synthesized by Kopecek in
1971. It still possesses the “smart” name because they respond to the stimulus by a change in
physical or chemical behavior.
Hydrogels are defined as three-dimensional structures that absorb water in large quantities
without dissolving into it. Water can not be removed either under pressure [58]. For example,
administration of timolol in the form of drops requires two administrations per day, and only
one application per day as a gel [129].
Chitosan dissolved in acidic solution and neutralized with β-glycerophosphate undergoes a
sol-gel transformation at body temperature, favoring the transfer of protons from chitosan to
the weak base.
Because of the amino-positive groups, it is able to interact spontaneously with anionic polymers,
forming polyelectrolyte complexes (PECs) with an increased tendency to form hydrogels:
chitosan-chondroitin sulfate, chitosan dextran sulfate (Figure 5, chitosan alginate [130]. A gel
based on chitosan and dextran sulfate was proposed for the ciprofloxacin release study. It has
been chemically characterized, morphologically, in terms of stability and concentration in the
active substance. Among the analytical techniques used are FTIR, SEM and DSC. Ciprofloxacin
release in simulated lacrimal fluid was determined using a UV-Vis spectrometer. The eye toler-
ance test was evaluated using HET-CAM (Hen’s egg test chorioallantoic membrane). The result
of the study was a non-irritating product that provides ciprofloxacin release for 21 h in the
treatment of susceptible germs infections [131].
Figure 5. Steps in formation of chitosan-dextran sulfate gel, illustrating the technique described by Jain et al. [131].
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The main advantage of this type of gels is the sustained release of the active substance and the
absence of blurred vision. Due to the increased contact time with the eye surface, the bioavail-
ability of the active substance is increased, the frequency of administration is reduced [132].
A gel composed of 15% pluronic and 0.1% chitosan with a ciprofloxacin’s release efficiency of
46.61  0.41% and a time release of 1.94  0.27 h was developed by Varshosaz et al. Ciproflox-
acin release was determined by the dissolution method in artificial tear solution up to 8 h, and
the samples were analyzed spectrophotometrically at 272.4 nm. Rheologic behavior and phase
transition temperature (PCT) were determined using a Cup and Bob viscometer. The formula-
tion was kept liquid at pH 4 and 25C and gel transformed to pH 7.4 and 37C [133].
From several formulations analyzed, Gupta et Vyas proposed a mixture of 0.4% Carbopol and
0.5% chitosan as an optimal ocular drug release system for timolol maleate. It is in a liquid
state at room temperature and pH 6 and is a gel under the action of tear fluid at pH 7.4. The
formulations were analyzed: pH, viscosity, swelling capacity and concentration in active sub-
stance. According to the studies, substance delivery followed Fick’s law for 24 h [134].
Zaki et al. attempted to incorporate ketorolac tromethamine into various hydrogels for oph-
thalmic administration. As polymers, chitosan and Carbopol 940 were used in different con-
centrations. The visual aspect, pH, viscosity, in vitro delivery behavior and stability were
analyzed. The best formulation according to the authors would be the one with 0.5% chitosan
in composition [135].
A gel based on chitosan and dextran sulfate was proposed for the ciprofloxacin release study. It
has been chemically characterized, morphologically, in terms of stability and concentration in
the active substance. Among the analytical techniques used are FTIR, SEM and DSC. Cipro-
floxacin release in simulated lacrimal fluid was determined using a UV-Vis spectrometer. The
eye tolerance test was evaluated using HET-CAM (Hen’s egg test chorioallantoic membrane).
The result of the study was a non-irritating product that provides ciprofloxacin release for 21 h
in the treatment of susceptible germs infections [136].
The aim of a study initiated by Gilhotra et al. is to evaluate the alginate-chitosan eye film with
atenolol in the treatment of glaucoma. The study showed that the addition of Ca gluconate
leads to an increased release of atenolol from the chitosan-alginate matrix without the desired
sustained effect [130].
Another study proposes a corneal membrane composed of chitosan and collagen. The mem-
brane was prepared by dissolving chitosan in collagen in varying proportions, followed by the
addition of 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide as a crosslinker. The membrane
was characterized in terms of mechanical properties, contact angle and optical transmittance.
In vitro cell culture studies have shown that collagen does not influence cell morphology,
viability with good compatibility [137].
Fabiano et al. formulated a chitosan and β-glycerophosphate gel for incorporation of
transcorneal 5-fluorouracil nanoparticles. The sol-gel transition takes place in the range of
30–35C. The concentration in active substance is kept constant for 7 h after administration.
The system is a potential candidate for optimal 5-fluorouracil release at eye level [138].
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2.3.8. Inserts and implants
Intravitreal injections are the most common method of administering drugs to the posterior
segment of the eye. They can be indicated in conditions such as age-related macular degener-
ation (AMD) with monoclonal antibodies such as bevacizumab (Avastin) or ranibizumab
(Lucentis).
An alternative to injections is ophthalmic implants such as Vitrasert (ganciclovir), Retisert
(fluocinolone acetonide), Iluvien (fluocinolone acetonide) and Ozurdex (dexamethasone) [139].
Ozurdex is bioerodible [140].
Ophthalmic inserts are solid, semi-solid, sterile, thin, multilayer, impregnated with active sub-
stance and placed on the conjunctival sac. Following studies, they have demonstrated increased
retention time, sustained release for a longer period of time, dosage accuracy, reduced frequency
of administration and lack of preservatives with irritant potential. They can be classified as
solubles (with natural or synthetic polymers, insolubles (Ocusert—diffusion mechanism of
release; or soft contact lenses—osmosis mechanism) and bioerodibles (Lacrisert) 6 [141].
Chitosan-based ocular inserts have been designed as an alternative to the release of brimonidine
tartrate in the treatment of glaucoma. Characterization of inserts was performed from an analyt-
ical point of view using FTIR, SEM and DSC. Swelling capacity, active substrate release profile,
in vitro bioavailability on Muller cells were also studied. The results of the study were that
brimonidine tartrate was physically dispersed between the polymer chains. The inserts release
the active substance for 30 days without adverse effects. They also have the advantage of being
free of preservatives [142].
Foureaux et al. studied the effects of some antiglaucoma inserts from chitosan. The inserts
having diminazene aceturate as active substance were prepared by casting technique and
analyzed for swallow capacity, analytically for FTIR, DSC and SEM. Quantification of the
active substance from the inserts was performed with the UV-Vis spectrometer and in vitro
release studies using a Franz cell. The authors concluded that inserts reduce intraocular
pressure by up to 4 weeks [143].
Upadhyaya et al. prepared chitosan-based inserts by casting method for levofloxacin release at
the eye level. It has been observed that PVP addition increases levofloxacin release rate. Based
on in vitro delivery studies, it was concluded that ocular inserts are suitable for the release of
the active substance over 24 h and are useful in the treatment of bacterial infections [144].
The purpose of the study initiated by Franca et al. is to evaluate the effectiveness of some
chitosan-based inserts with bimatoprost. The sustained release of the active substance is
performed according to in vitro studies at 8 h, which recommends it as a potential alternative
in the treatment of glaucoma [145].
2.3.9. Contact lenses
Theoretically, ocular administration of active substances through contact lenses is 35 times
more effective than eye drops.
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Soft contact lenses are generally made of hydrogels due to their biocompatibility and transparency.
Incorporation of the active substances is accomplished by wetting the lenses with a drug
solution, inclusion in a polymeric mixture or in a colloidal structure such as nanoemulsion,
nanosuspension, liposomes dispersed in the lens, ligand grafting on the hydrophilic matrix
with the formation of inclusion complexes with the drug [146]. If the drug’s affinity for the lens
is too high, the formulation is stable, but the release is difficult. If the drug is weakly retained
by the lens, the release is rapid, followed by a steep decline [147].
Hydration is required when using contact lenses, allowing oxygen to penetrate the cornea.
Since the lack of hydration results in dry eye syndrome [148], it is recommended to use contact
lenses in association with eye drops [149].
Several advantages are attributed to the use of hydrogel contact lenses: good light transmission,
chemical stability and high mechanical properties, increased permeability for oxygen [150].
Behl et al. proposed to increase eye bioavailability of dexamethasone by incorporating it into
chitosan nanoparticles which were subsequently imprinted in pHEMA hydrogel contact
lenses. Particle size was analyzed by SEM, interactions between dexamethasone and
nanoparticles by FTIR. They also studied in vitro release studies. Obtaining an average trans-
mittance of 95–98% demonstrates lens clarity, and dexamethasone release was 55.75% in
22 days. According to the study, the bioavailability of dexamethasone was 72% compared to
eye drops within the first 10 days. The conclusions of the study were that the application of
contact lenses with chitosan nanoparticles in which dexamethasone was incorporated, leads to
therapeutically positive responses [151].
The association of chitosan and gelatin has been shown to be beneficial in the preparation of
contact lenses according to Xin-Yuan et al. The film was characterized by permeability, trans-
mittance, water absorption and mechanical properties. The study demonstrated that the film is
biocompatible, transparent, permeable and gelatin association has increased water absorption
and oxygen permeability [152].
Wearing contact lenses can create certain problems, so Hu et al. have proposed the assembly of
a chitosan/hyaluronic acid multilayer on the surface of the lens in order to improve the surface
properties such as wettability or deposition of proteins. The chitosan/hyaluronic acid multi-
layer was loaded with norfloxacin and timolol, respectively. It was observed that the multi-
layer steadily releases norfloxacin in 1 h, and timolol in 30 min. The purpose of this study is to
increase the hydrophilic character of the lenses, increase the water retention and reduce the
deposition of the proteins [153].
2.3.10. Mini-tablets
Mini-tablets are devices with a diameter of approximately 2–4 mm inserted into the conjuncti-
val sac. They can gel in the presence of lacrimal fluid or the matrix can dissolve, releasing the
active substance [154].
Among the advantages of mini-tablets are easy administration, increased compliance, sustained
release, lack of irritation and lack of dilution of drug substance [155].
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EL-Gawad et al. prepared ocular mini-tablets based on various polymeric matrices including
chitosan for the controlled release of piroxicam. The friability studies showed a 2.36%weight loss
in the chitosan mini-tablets, which means they can resist the stresses that occur when adminis-
tered without producing a foreign body sensation. They also have the ability to quickly disinte-
grate when administered [156].
Refai and Tag aimed to formulate and evaluate some aciclovir eye mini-tablets to treat kerati-
tis. The spongy nature of the mini-tablets provides fast hydration and gelling at the eye level,
reducing foreign body sensation. Several mini-tablets with different polymers including
chitosan have been evaluated. Rheological studies have shown pseudoplastic behavior. Opti-
mal release of acyclovir was in the case of chitosan mini-tablets. The chitosan mini-tablets were
chosen for the significant sustained release of acyclovir and bioadhesive properties, and the
corneal permeability is superior to the Zovirax ointment [157].
Verestiuc et al. were prepared acrylic-functionalized chitosan hydrogels with N-isopropyl
acrylamide or 2-hydroxyethyl methacrylate monomers, then pressed to obtain mini-tablets.
These have been evaluated for the controlled release capacity of some drugs at the ophthalmic
level. By comparison, interpolymeric complexes and pure chitosan were analyzed. The effects
of the structure and composition of the network on the properties of swelling, adherence and
release of active substances such as chloramphenicol, atropine, pilocarpine or norfloxacin were
studied. In vivo studies in rabbits which received pilocarpine indicated that mini-tablets based
on chitosan and 2-hydroxyethylmethacrylate are optimal carriers for the delivery of the thera-
peutic agent [158].
Another study aims to develop and study mini-tablets of sodium alginate, calcium gluconate
and chitosan for the purpose of ocular delivery of gatifloxacin. In vivo tests and irritation
studies were performed on rabbits. The release was 95–99% on 6–24 h according to the authors.
It has been observed that this is enhanced by the increased addition of calcium gluconate. Also,
the mini-tablets have been found to be non-irritating and the chitosan and alginate mini-tablets
have good antimicrobial properties [159].
3. Conclusions
The human eye is a small, sensitive and complex organ that represents a continuous challenge
in pharmaceutical research. The reduced bioavailability (below 5%) of drug substances as eye
drops due to factors such as nasolacrimal drainage, blinking reflexes or ocular barriers
has made it necessary to develop new ways of administration. Due to its properties, chitosan
is considered a good candidate as an excipient in various pharmaceutical formulations for
ocular administration. It is biocompatible, biodegradable and non-toxic. It has mucoadhesive
properties by interacting with sialic acid residues from the mucin structure and pseudoplastic
and viscolectric properties similar to lacrimal fluid. Thiolated derivatives, called thiomers,
have enhanced mucoadhesive properties and improve the permeability of active substances
through ocular barriers.
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The use of chitosan in ophthalmic delivery systems such as nanoparticles, nanomicelles,
nanosuspensions, liposomes, microemulsions, microspheres, in situ gels, inserts, contact lenses
or mini-tablets increases the retention time of the active substance at the eye level with
enhancing its bioavailability. Thus, it will decrease the frequency of administration and will
increase patient’s compliance with improving his quality of life. These chitosan-based systems
do not cause irreversible alterations in ocular barriers, do not damage the tissues, or interfere
with tear fluid.
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